U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H29N3O6
Molecular Weight 479.526
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICARDIPINE

SMILES

CC1=C(C(c2cccc(c2)N(=O)=O)C(=C(C)N1)C(=O)OCCN(C)Cc3ccccc3)C(=O)OC

InChI

InChIKey=ZBBHBTPTTSWHBA-UHFFFAOYSA-N
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C26H29N3O6
Molecular Weight 479.526
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00622 | https://www.drugs.com/cdi/nicardipine.html | https://www.ncbi.nlm.nih.gov/pubmed/2772808 | http://reference.medscape.com/drug/cardene-iv-nicardipine-342377

Nicardipine is a potent calcium channel blockader with marked vasodilator action used to treat high blood pressure and angina. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Originator

Sources: JP 49109384

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.25 µM [IC50]
2.66 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
35.1 ng/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.1 ng/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.9 ng/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18.8 ng/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1426.2 ng × h/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2996.1 ng × h/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7510.7 ng × h/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
846.3 ng × h/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14 h
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.9 h
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20.6 h
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
NICARDIPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Other AEs: Slurred speech, Hypotension...
Other AEs:
Slurred speech
Hypotension (marked)
Bradycardia
Palpitations
Flushing
Drowsiness
Confusion
Sources: Page: p.21
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Disc. AE: Hypotension, Headache...
AEs leading to
discontinuation/dose reduction:
Hypotension
Headache
Tachycardia
Sources: Page: p.21
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Disc. AE: Rash, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Rash (0.9%)
Diarrhea (0.9%)
Tachycardia (0.9%)
Blurred vision (0.6%)
Chest pain (0.6%)
Face edema (0.6%)
Myocardial infarct (0.6%)
Vasodilatation (0.6%)
Vomiting (0.6%)
Sources: Page: p.10
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Disc. AE: Headache, Palpitation...
AEs leading to
discontinuation/dose reduction:
Headache (2.5%)
Palpitation (2.2%)
Dizziness (1.9%)
Asthenia (1.9%)
Pedal edema (1.2%)
Nausea (1.2%)
Sources: Page: p.9
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Disc. AE: Angina...
AEs leading to
discontinuation/dose reduction:
Angina
Sources: Page: p.5
AEs

AEs

AESignificanceDosePopulation
Bradycardia
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Confusion
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Drowsiness
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Flushing
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Palpitations
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Slurred speech
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Hypotension marked
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Headache Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Hypotension Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Tachycardia Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Blurred vision 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Chest pain 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Face edema 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Myocardial infarct 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vasodilatation 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vomiting 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Diarrhea 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Rash 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Tachycardia 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Nausea 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Pedal edema 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Asthenia 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Dizziness 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Palpitation 2.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Headache 2.5%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Angina Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Antihypertensive and renal effects of nicardipine.
1984 Jul
The calcium antagonist, nicardipine, inhibits antigen-stimulated and anti-IgE-induced histamine release from basophilic leucocytes of atopic asthmatics.
1985 Aug
Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine.
1985 May
Haemodynamic analysis of the effects of nicardipine and metoprolol alone and in combination in coronary artery disease.
1985 Nov
Effects of nicardipine on left ventricular function and energetics in man.
1986 Mar
Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial.
1986 Oct 1
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.
1987
Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.
1987
Nicardipine and urinary retention.
1987 Dec 18
Metabolic and hemodynamic effects of nicardipine during pacing-induced angina pectoris.
1987 Feb 1
The potential beneficial effect of nicardipine in a rat model of transient forebrain ischemia.
1987 May
Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs.
1987 Oct 6
Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia.
1988
Serum lipid changes in patients with mild to moderate essential hypertension taking nicardipine and propranolol.
1988 Dec
Endogenous opiate system and dihydropyridine-induced central regulation of sympathetic tone in rats.
1988 Dec 6
Calcium channel inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats.
1989 Aug 3
Intravenous nicardipine for the treatment of severe hypertension. A double-blind, placebo-controlled multicenter trial.
1989 Dec
[Antihypertensive effect and tolerability of slow-release nicardipine].
1989 Feb
[Calcium intestinal absorption in normotensive and essential hypertensive subjects before and after nicardipine].
1989 Jul
Erythromelalgia induced by nicardipine.
1989 Jul 29
Erythromelalgia induced by nicardipine.
1989 Jun 10
Haemodynamic responses to nicardipine in humans anaesthetised with halothane.
1989 May
Erythromelalgia induced by nicardipine (inverse Raynaud's phenomenon?).
1989 May 6
Nicardipine decreases blood pressure and heart rate at nucleus tractus solitarii of spontaneously hypertensive rats.
1989 Nov
Inotropic effect of nicardipine in patients with heart failure: assessment by left ventricular end-systolic pressure-volume analysis.
1989 Nov 1
Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine.
1990 Apr
[Blood pressure monitoring in aged hypertensive patients treated with sustained-release nicardipine or nifedipine].
1990 Dec 8
Randomized double-blind comparison of side effects of nicardipine and nifedipine in angina pectoris. The Nicardipine Investigators Group.
1990 Feb
Acute antianginal hemodynamic effects of nicardipine in coronary artery disease.
1990 Feb
Oxytocin-induced penile erection and yawning: role of calcium and prostaglandins.
1990 Mar
Nicardipine reduces the cardio-respiratory toxicity of intravenously administered bupivacaine in rats.
1990 Nov
Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up.
1991
[The hemodynamics of oral nicardipine determined by radioisotope ventriculography in patients with ischemic cardiopathy].
1991 Jan-Feb
Heterogeneous interference of nicardipine, verapamil, and diltiazem with forearm arteriolar responsiveness to adrenergic stimulation in hypertensive patients.
1991 Jul
Nicardipine and vascular hypertrophy.
1991 Jul
Co-suppression by nicardipine, a calcium antagonist, of induction of microsomal lauric acid hydroxylation with peroxisome proliferation in clofibrate-treated rat liver.
1991 May
Profile of capsaicin-induced mouse ear oedema as neurogenic inflammatory model: comparison with arachidonic acid-induced ear oedema.
1993 Dec
Nifedipine and nicardipine potentiate glucagon-stimulated glycogenolysis in primary cultures of rat hepatocytes.
1993 Sep
Effects of a novel dihydropyridine calcium antagonist on venous capacitance in Wistar-Kyoto rats.
1994
Protective effect of nicardipine treatment on renal microanatomical changes in spontaneously hypertensive rats.
1994 Jul
Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine.
1995 Sep
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Antihypertensive treatment of acute cerebral hemorrhage.
2010 Feb
Comparison between atosiban and nicardipine in inducing hypotension during in-utero transfers for threatening premature delivery.
2010 Jun
Augmentation of 3-methylcholanthrene-induced bioactivation in the human hepatoma cell line HepG2 by the calcium channel blocker nicardipine.
2010 Mar
Nicardipine infusion for blood pressure control in patients with subarachnoid hemorrhage.
2010 Oct
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma.
2011 Mar 1
Deltamethrin, a type II pyrethroid insecticide, has neurotrophic effects on neurons with continuous activation of the Bdnf promoter.
2012 Feb
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Sample Use Guides

Hypertension. PO: 20-40 mg (conventional) q8hr or 30-60 mg (extended release) q12hr; IV: 5 mg/hr by slow infusion (50 mL/hr) initially; may be increased by 2.5 mg/hr every 15 minutes; not to exceed 15 mg/hr Chronic Stable Angina. 20-40 mg (conventional) PO q8h
Route of Administration: Other
The growth effects of EGF and nicardipine on U251MG cultured in serum-free and serum-supplemented (10% fetal bovine serum, FBS) medium respectively were observed by MTT colorimeritric analysis. EGF significantly enhanced the growth of U251MG cells in a dose-dependent manner in serum-free medium. The maximal effect was seen at 20 ng/ml. The effects of EGF approximated those obtained in 10% FBS. Nicardipine decreased U251MG cell proliferation, especially in serum-supplemented medium, and completely blocked the growth-stimulated effects of EGF. The combined effects of EGF (10 ng/ml) and nicardipine equaled those of nicardipine alone.
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:02:27 UTC 2021
Edited
by admin
on Fri Jun 25 23:02:27 UTC 2021
Record UNII
CZ5312222S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICARDIPINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NICARDIPINE [WHO-DD]
Common Name English
2-(BENZYLMETHYLAMINO)ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-METHYL 5-(2-(METHYL(PHENYLMETHYL)AMINO)ETHYL) ESTER
Systematic Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, METHYL 2-(METHYL(PHENYLMETHYL)AMINO)ETHYL ESTER
Common Name English
NICARDIPINE [VANDF]
Common Name English
NICARDIPINE [MI]
Common Name English
(+/-)-NICARDIPINE
Common Name English
NICARDIPINE [INN]
Common Name English
PERPIDINE
Brand Name English
NICARDIPINE (STN)
Common Name English
Classification Tree Code System Code
WHO-ATC C08CA04
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
FDA ORPHAN DRUG 712819
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
NDF-RT N0000007556
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
NCI_THESAURUS C333
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
NDF-RT N0000175421
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
WHO-VATC QC08CA04
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
NDF-RT N0000000069
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
LIVERTOX 682
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C66879
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
CAS
55985-32-5
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
EPA CompTox
55985-32-5
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
MESH
D009529
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
EVMPD
SUB09225MIG
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
DRUG CENTRAL
1909
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
DRUG BANK
DB00622
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
PUBCHEM
4474
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
IUPHAR
2559
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
NDF-RT
N0000187062
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY Cytochrome P450 2C8 Inhibitors [MoA]
ChEMBL
CHEMBL1484
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
MERCK INDEX
M7850
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY Merck Index
RXCUI
7396
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY RxNorm
INN
4745
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
ECHA (EC/EINECS)
259-932-3
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
LACTMED
Nicardipine
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
FDA UNII
CZ5312222S
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
NDF-RT
N0000182137
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
WIKIPEDIA
NICARDIPINE
Created by admin on Fri Jun 25 23:02:28 UTC 2021 , Edited by admin on Fri Jun 25 23:02:28 UTC 2021
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC